These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 33197449)

  • 21. Strain types and antimicrobial resistance patterns of Clostridium difficile isolates from the United States, 2011 to 2013.
    Tickler IA; Goering RV; Whitmore JD; Lynn AN; Persing DH; Tenover FC;
    Antimicrob Agents Chemother; 2014 Jul; 58(7):4214-8. PubMed ID: 24752264
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dogs as carriers of virulent and resistant genotypes of Clostridioides difficile.
    Finsterwalder SK; Loncaric I; Cabal A; Szostak MP; Barf LM; Marz M; Allerberger F; Burgener IA; Tichy A; Feßler AT; Schwarz S; Monecke S; Ehricht R; Ruppitsch W; Spergser J; Künzel F
    Zoonoses Public Health; 2022 Sep; 69(6):673-681. PubMed ID: 35546073
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of berberine chloride and/or its combination with vancomycin on the growth, biofilm formation, and motility of Clostridioides difficile.
    Wultańska D; Piotrowski M; Pituch H
    Eur J Clin Microbiol Infect Dis; 2020 Jul; 39(7):1391-1399. PubMed ID: 32140903
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Defining the vulnerable period for re-establishment of Clostridium difficile colonization after treatment of C. difficile infection with oral vancomycin or metronidazole.
    Abujamel T; Cadnum JL; Jury LA; Sunkesula VC; Kundrapu S; Jump RL; Stintzi AC; Donskey CJ
    PLoS One; 2013; 8(10):e76269. PubMed ID: 24098459
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular epidemiology and antimicrobial susceptibility of human Clostridium difficile isolates from a single institution in Northern China.
    Wang B; Lv Z; Zhang P; Su J
    Medicine (Baltimore); 2018 Jun; 97(25):e11219. PubMed ID: 29924052
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High sporulation and overexpression of virulence factors in biofilms and reduced susceptibility to vancomycin and linezolid in recurrent Clostridium [Clostridioides] difficile infection isolates.
    Tijerina-Rodríguez L; Villarreal-Treviño L; Baines SD; Morfín-Otero R; Camacho-Ortíz A; Flores-Treviño S; Maldonado-Garza H; Rodríguez-Noriega E; Garza-González E
    PLoS One; 2019; 14(7):e0220671. PubMed ID: 31365590
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The interplay between microbiome dynamics and pathogen dynamics in a murine model of Clostridium difficile Infection.
    Reeves AE; Theriot CM; Bergin IL; Huffnagle GB; Schloss PD; Young VB
    Gut Microbes; 2011; 2(3):145-58. PubMed ID: 21804357
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reduced acquisition and overgrowth of vancomycin-resistant enterococci and Candida species in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection.
    Nerandzic MM; Mullane K; Miller MA; Babakhani F; Donskey CJ
    Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S121-6. PubMed ID: 22752860
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhanced preservation of the human intestinal microbiota by ridinilazole, a novel Clostridium difficile-targeting antibacterial, compared to vancomycin.
    Thorpe CM; Kane AV; Chang J; Tai A; Vickers RJ; Snydman DR
    PLoS One; 2018; 13(8):e0199810. PubMed ID: 30071046
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oral teicoplanin administration suppresses recurrence of Clostridioides difficile infection: Proof of concept.
    Tanaka Y; Tashiro S; Ikegami S; Enoki Y; Taguchi K; Matsumoto K
    Anaerobe; 2023 Dec; 84():102789. PubMed ID: 37879532
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sequence-Based Identification of Metronidazole-Resistant Clostridioides difficile Isolates.
    Smits WK; Harmanus C; Sanders IMJG; Bry L; Blackwell GA; Ducarmon QR; de Oliveira Ferreira E; Kuijper EJ
    Emerg Infect Dis; 2022 Nov; 28(11):2308-2311. PubMed ID: 36286226
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of antibiotic to induce Clostridioides difficile-susceptibility and infectious strain in a mouse model of Clostridioides difficile infection and recurrence.
    Castro-Córdova P; Díaz-Yáñez F; Muñoz-Miralles J; Gil F; Paredes-Sabja D
    Anaerobe; 2020 Apr; 62():102149. PubMed ID: 31940467
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fidaxomicin versus metronidazole, vancomycin and their combination for initial episode, first recurrence and severe Clostridioides difficile infection - An observational cohort study.
    Polivkova S; Krutova M; Capek V; Sykorova B; Benes J
    Int J Infect Dis; 2021 Feb; 103():226-233. PubMed ID: 33188906
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin.
    Peláez T; Alcalá L; Alonso R; Rodríguez-Créixems M; García-Lechuz JM; Bouza E
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1647-50. PubMed ID: 12019070
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cadazolid vs Vancomycin for the Treatment of Clostridioides difficile Infection: Systematic Review with Meta-analysis.
    Muhammad A; Simcha W; Rawish F; Sabih R; Albert E; Ali N
    Curr Clin Pharmacol; 2020; 15(1):4-10. PubMed ID: 31376824
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fecal pharmacokinetics/pharmacodynamics characteristics of fidaxomicin and vancomycin against Clostridioides difficile infection elucidated by in vivo feces-based infectious evaluation models.
    Tashiro S; Taguchi K; Enoki Y; Matsumoto K
    Clin Microbiol Infect; 2023 May; 29(5):616-622. PubMed ID: 36574949
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Whole-genome sequencing demonstrates that fidaxomicin is superior to vancomycin for preventing reinfection and relapse of infection with Clostridium difficile.
    Eyre DW; Babakhani F; Griffiths D; Seddon J; Del Ojo Elias C; Gorbach SL; Peto TE; Crook DW; Walker AS
    J Infect Dis; 2014 May; 209(9):1446-51. PubMed ID: 24218500
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antimicrobial susceptibility and ribotypes of Clostridium difficile isolates from a Phase 2 clinical trial of ridinilazole (SMT19969) and vancomycin.
    Snydman DR; McDermott LA; Thorpe CM; Chang J; Wick J; Walk ST; Vickers RJ
    J Antimicrob Chemother; 2018 Aug; 73(8):2078-2084. PubMed ID: 29718329
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Did Clostridioides difficile testing and infection rates change during the COVID-19 pandemic?
    Hawes AM; Desai A; Patel PK
    Anaerobe; 2021 Aug; 70():102384. PubMed ID: 34029702
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aryl-alkyl-lysines: Novel agents for treatment of C. difficile infection.
    Ghosh C; AbdelKhalek A; Mohammad H; Seleem MN; Haldar J
    Sci Rep; 2020 Mar; 10(1):5624. PubMed ID: 32221399
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.